Your browser doesn't support javascript.
loading
[Overexpression of lncRNA FEZF1-AS1 promotes progression of non-small cell lung cancer via the miR-130a-5p/CCND1 axis].
Li, F; Xiang, J; Liu, J; Wang, X; Jiang, H.
Affiliation
  • Li F; Department of Tumor Radiotherapy, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
  • Xiang J; Department of Respiratory and Critical Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
  • Liu J; Department of Respiratory and Critical Medicine, Qijiang District People's Hospital, Chongqing 401420, China.
  • Wang X; Department of Respiratory and Critical Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
  • Jiang H; Department of Respiratory and Critical Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Nan Fang Yi Ke Da Xue Xue Bao ; 44(5): 841-850, 2024 May 20.
Article in Zh | MEDLINE | ID: mdl-38862441
ABSTRACT

OBJECTIVE:

To explore the molecular mechanism by which FEZF1-AS1 overexpression promotes progression of nonsmall cell lung cancer (NSCLC) via the miR-130a-5p/CCND1 axis.

METHODS:

TCGA database was used to analyze FEZF1-AS1 expression levels in NSCLC. FEZF1-AS1 expression was detected by qRT-PCR in clinical specimens of NSCLC tissues and NSCLC cell lines, and its correlation with clinical features of the patients were analyzed. The binding sites of FEZF1-AS1 with hsa-miR-130a-5p and those of hsa-miR-130a-5p with CCND1 were predicted. CCK8 assay, clone formation assay, scratch assay, and Transwell assay were employed to examine the effects of FEZF1-AS1 knockdown and hsa-miR-130a-5p inhibitor on proliferation, invasion, and migration abilities of lung cancer cell lines. Dual luciferase assay was used to verify the binding of FEZF1-AS1 with hsa-miR-130a-5p and the binding of hsa-miR-130a-5p with CCND1. Western blotting was performed to detect the changes in CCND1 protein expression level in H1299 and H358 cells following FEZF1-AS1 knockdown and treatment with hsa-miR-130a-5p inhibitor.

RESULTS:

FEZF1-AS1 was highly expressed in NSCLC tissues in close correlation with lymph node metastasis and also in H1299 and H358 cell lines (all P < 0.05). FEZF1-AS1 knockdown obviously reduced proliferation, migration, and invasion abilities of NSCLC cells (P < 0.05). Dual luciferase assay confirmed the binding of hsa-miR-130a-5p with FEZF1-AS1 and CCND1 (P < 0.05), and hsa-miR-130a-5p inhibitor significantly inhibited proliferation, migration, and invasion of NSCLC cells (P < 0.05). FEZF1-AS1 knockdown significantly reduced CCND1 protein expression in NSCLC cells, and this effect was strongly inhibited by treatment with hsa-miR-130a-5p inhibitor (P < 0.05).

CONCLUSION:

FEZF1-AS1 is highly expressed in NSCLC tissue in close correlation with lymph node metastasis to promote cancer progression through the miR-130a-5p/CCND1 axis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cell Movement / Carcinoma, Non-Small-Cell Lung / Cyclin D1 / MicroRNAs / Cell Proliferation / RNA, Long Noncoding / Lung Neoplasms Limits: Humans Language: Zh Journal: Nan Fang Yi Ke Da Xue Xue Bao Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cell Movement / Carcinoma, Non-Small-Cell Lung / Cyclin D1 / MicroRNAs / Cell Proliferation / RNA, Long Noncoding / Lung Neoplasms Limits: Humans Language: Zh Journal: Nan Fang Yi Ke Da Xue Xue Bao Year: 2024 Document type: Article Affiliation country: